DE60137525D1 - Peg-modifiziertes erythropoietin - Google Patents

Peg-modifiziertes erythropoietin

Info

Publication number
DE60137525D1
DE60137525D1 DE60137525T DE60137525T DE60137525D1 DE 60137525 D1 DE60137525 D1 DE 60137525D1 DE 60137525 T DE60137525 T DE 60137525T DE 60137525 T DE60137525 T DE 60137525T DE 60137525 D1 DE60137525 D1 DE 60137525D1
Authority
DE
Germany
Prior art keywords
peg
epo
conjugated
native
erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137525T
Other languages
English (en)
Inventor
Teruo Nakamura
Yasuo Sekimori
Minoru Machida
Hiromitsu Kawata
Hajime Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60137525D1 publication Critical patent/DE60137525D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60137525T 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin Expired - Lifetime DE60137525D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000315421 2000-10-16
PCT/JP2001/008539 WO2002032957A1 (fr) 2000-10-16 2001-09-28 Erythropoietine modifiee par peg

Publications (1)

Publication Number Publication Date
DE60137525D1 true DE60137525D1 (de) 2009-03-12

Family

ID=18794529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137525T Expired - Lifetime DE60137525D1 (de) 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin

Country Status (8)

Country Link
US (2) US20040082765A1 (de)
EP (1) EP1333036B1 (de)
JP (1) JP5170931B2 (de)
AT (1) ATE421535T1 (de)
AU (1) AU2001290312A1 (de)
DE (1) DE60137525D1 (de)
ES (1) ES2320101T3 (de)
WO (1) WO2002032957A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5207590B2 (ja) * 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
KR20050086948A (ko) 2002-12-27 2005-08-30 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
EP1471153A3 (de) * 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transkriptionsaktivitätsassay
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
EP1691841B1 (de) * 2003-12-10 2020-09-09 Nektar Therapeutics Zusammensetzungen mit zwei verschiedenen gruppen von polymer-wirkstoff-konjugaten
PT1699915E (pt) * 2003-12-30 2010-08-31 Augustinus Bader Utilização de eritropoietina para a regeneração de tecido hepático
WO2006089228A2 (en) * 2005-02-16 2006-08-24 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
WO2006135930A2 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
WO2007026772A1 (ja) * 2005-08-31 2007-03-08 Kaneka Corporation ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
MX2008012600A (es) 2006-03-31 2008-12-12 Baxter Int Factor viii pegilado.
US8299026B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of erythropoietin (EPO)
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
CA2659990C (en) * 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
EP2532369B1 (de) 2006-12-15 2017-11-01 Baxalta GmbH Faktor-VIIa-(poly)sialsäurekonjugat mit verlängerter In-Vivo-Halbwertszeit
WO2009089542A2 (en) 2008-01-11 2009-07-16 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
AR078044A1 (es) 2009-05-20 2011-10-12 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
RU2549986C2 (ru) 2009-09-15 2015-05-10 Канека Корпорейшн Модифицированный эритропоэтин, к которому присоединена водорастворимая длинноцепочечная молекула
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2502646B2 (ja) 1988-01-19 1996-05-29 松下電器産業株式会社 バ―ナ
JPH029900A (ja) * 1988-04-12 1990-01-12 Kirin Amgen Inc 修飾エリスロポエチン
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
FI935485A (fi) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
BR9711009A (pt) * 1996-08-02 1999-08-17 Ortho Mcneil Pharm Inc Polipeptidio tendo um polimero solÚvel em gua n-terminal covalentemente ligado
EP0921817B1 (de) * 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylationsverfahren
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
EP1135493A2 (de) * 1998-11-30 2001-09-26 Eli Lilly And Company Erythropoietische substanzen
NZ513077A (en) * 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
CN1376164A (zh) 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem

Also Published As

Publication number Publication date
ATE421535T1 (de) 2009-02-15
ES2320101T3 (es) 2009-05-19
EP1333036A1 (de) 2003-08-06
JP5170931B2 (ja) 2013-03-27
WO2002032957A1 (fr) 2002-04-25
JPWO2002032957A1 (ja) 2004-02-26
EP1333036B1 (de) 2009-01-21
EP1333036A4 (de) 2004-09-29
US20060276634A1 (en) 2006-12-07
US20040082765A1 (en) 2004-04-29
AU2001290312A1 (en) 2002-04-29
US8022191B2 (en) 2011-09-20

Similar Documents

Publication Publication Date Title
ATE421535T1 (de) Peg-modifiziertes erythropoietin
DE60006100D1 (de) Lang wirkende insulinotrope peptide
ATE463260T1 (de) Ortspezifische duale pegylation von proteine
ATE551362T1 (de) Peptide, die den blutzuckergehalt senken
BR0010757A (pt) Inibidores de peptìdeo de fusão de longa duração de infecção viral
ATE550041T1 (de) Transglutaminase-vermittelte konjugation von peptiden
ATE364654T1 (de) Polyamideketten von genauer länge und deren konjugate mit proteinen
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
AU2001296962A1 (en) Pegylated interleukin-10
ATE89743T1 (de) Conjugate dichter sterne.
EA200400067A1 (ru) Конъюгаты гксф
CO5190661A1 (es) Derivados de la eritropoyetina
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
DK1274728T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af anæmi
DE60144439D1 (de) Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
DE69432141D1 (de) Taxane mit furyl-oder thienyl substituierten seitenketten
ATE471956T1 (de) Verzweigte polyalkylenglykole
DK0557199T3 (da) Polyethylenglycol-hirudin-konjugater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af tromboser
CA2373252A1 (en) Long lasting anti-angiogenic peptides
TR200200599T2 (tr) İnsan insülini monomerik analogları.
WO2004014951A3 (en) Binding molecules
ATE313796T1 (de) Konjugate definierter stöchiometrie
CY1115962T1 (el) Πεπτιδια που μειωνουν τα επιπεδα της γλυκοζης στο αιμα
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
ITAR930014A1 (it) Snodo rotante per collane e bracciali tubolari

Legal Events

Date Code Title Description
8364 No opposition during term of opposition